The removal of LDL from plasma and interstitial fluid is mediated via receptor and nonreceptor pathways. We attempted to quantitate LDL catabolism via each of these pathways in subjects with MPD and control subjects. The total FCR of LDL apo B was measured using radiolabeled native LDL. The FCR of radiolabeled cyclohexanedione-modified LDL (CHD-LDL) was used to assess the nonreceptor-mediated catabolism of LDL. M uller first noted in 1930 1 that hypocholesterolemia is associated with myeloproliferative diseases (MPD). More recent reports confirmed the occurrence of reduced plasma total cholesterol concentrations in subjects with MPD 23 and stimulated us to initiate a series of studies aimed at delineating the pathophysiologic basis of this association. In our initial effort, we demonstrated significant reductions in low density lipoprotein (LDL) and high density lipoprotein cholesterol concentrations and noted an inverse relationship between the level of disease activity and LDL cholesterol. 4 We then proceeded to quantitate the rates of production and degradation of very low density lipoproteins (VLDL) and LDL using radiolabeled lipoproteins and specifically following 233
M uller first noted in 1930
1 that hypocholesterolemia is associated with myeloproliferative diseases (MPD). More recent reports confirmed the occurrence of reduced plasma total cholesterol concentrations in subjects with MPD 23 and stimulated us to initiate a series of studies aimed at delineating the pathophysiologic basis of this association. In our initial effort, we demonstrated significant reductions in low density lipoprotein (LDL) and high density lipoprotein cholesterol concentrations and noted an inverse relationship between the level of disease activity and LDL cholesterol. 4 We then proceeded to quantitate the rates of production and degradation of very low density lipoproteins (VLDL) and LDL using radiolabeled lipoproteins and specifically following 233 apoprotein B (apo B) as a marker of VLDL and LDL flux. These studies demonstrated that the reduced plasma LDL cholesterol concentrations in MPD were associated with an increased fractional catabolic rate (FCR) for LDL apo B. 5 LDL removal from plasma and interstitial fluid is mediated via receptor and nonreceptor pathways. Receptor-mediated LDL catabolism is dependent on the interaction of apo B with a specific cell-surface receptor. 6 ' 7 This interaction results in the internalization of the LDL particle which initiates a series of finely regulated metabolic reactions that together maintain cellular cholesterol levels. 89 Nonreceptor mediated LDL catabolism is undefined at this time and may include uptake of LDL particles via fluid phase endocytosis, nonspecific adsorbtive endocytosis, and phagocytosis. The recent demonstration by Mahley and his co-workers that specific modifications of arginine 10 and lysine 11 residues on apo B would inhibit receptor-mediated LDL catabolism offered investigators a means of estimating nonreceptor LDL catabolism in vivo. Shepherd et al. 12 used cyclohexanedione (CHD)-modified LDL, which is modified at arginine residues, in an attempt to quantitate the proportion of LDL catabolized via each pathway in normal subjects and in individuals with familial hypercholesterolemia (FH), a condition in which the total FCR for native LDL apo B is reduced. In the present study, we used CHD-LDL in an attempt to assess the role of nonreceptor-mediated LDL catabolism in subjects with MPD, a condition in which the total FCR for native LDL apo B is increased.
Methods

Subjects
Eleven individuals with MPD were studied. Their clinical characteristics are presented in Table 1 . All had received chemotherapy and/or had undergone phlebotomy at some time during their clinical course, but only one subject (No. 6) was receiving any chemotherapeutic agent (prednisone, 10 mg/day) at the time of the study. One subject (No. 4) was receiving aspirin daily because of thrombocytosis. The MPD subjects had no other diseases known to affect plasma lipid levels. Specifically, thyroid, liver, and kidney function tests were within normal limits. The subjects were all nutritionally stable and five of the eleven (Nos. 2, 4, 6, 8, 10) were maintaining regular work schedules. None was significantly debilitated by the disease. Ten control subjects were recruited by advertisement. None of these individuals had any medical problems, nor was taking any medications. The data for the native LDL turnover for several control and MPD subjects have been reported previously. 5 In order to compare control subjects and individuals with MPD to subjects with reduced total LDL catabolism, a mother and daughter with FH were also studied. Their family studies were consistent with both parents being heterozygous for FH and the daughter being homozygous for this disorder. Neither subject was receiving any medication at the time of study.
Protocol
All investigations were carried out in the General Clinical Research Center at the Mount Sinai Medical Center. The protocol was approved by the institutional review board and informed consent was obtained before all studies. MPD and control subjects consumed solid food diets consisting of 40% fat, 40% carbohydrate, and 20% protein. The ratio of polyunsaturated to saturated fat (P:S) was 0.4 and the diet included 150 mg cholesterol per 1000 kcal/day. Diets were started 3 to 7 days before plasmapheresis and continued throughout the study. The control subjects and MPD subject No. 8 were outpatients except for the first 36 hours of the LDL turnover study. The other ten MPD subjects and the two FH patients were inpatients for the entire protocol. The FH patients underwent identical studies except that their diets, which had been stable for 12 months, consisted of 25% fat, 55% carbohydrate, and 20% protein.
The P/S was 1.5, and their diets included 50 mg cholesterol per 1000 kcal/day.
Subjects underwent plasmapheresis and their plasma was used to isolate LDL by ultracentrifugation as previously described. 13 Aliquots of the LDL (d = 1.019-1.063) were then iodinated with either 12S I or 131 I by a modification 14 of the method of McFarlane. 15 One of the radiolabeled LDL preparations was then modified with CHD as described by Mahley et al. 10 The native and CHD-LDL preparations were diluted with human serum albumin (final concentration: 5%) and saline before administration and sterilized by passage through 0.45 fim filters.
All subjects received autologous radiolabeled native LDL 5 days after plasmapheresis. Six MPD, five normal control, and both FH subjects simultaneously received autologous radiolabeled CHD-LDL. In eight of these double studies, 125 I native LDL and 131 I CHD-LDL were used, while the isotopes were reversed in the remaining five studies. The protocol for the measurement of LDL turnover has been described previously.
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Animal Studies
The radiolabeled native and CHD-LDL preparations from several of the patient and control subjects were injected into cynomolgus monkeys (Macaca fasicularis) in order to compare the removal rates of each form of LDL in a distinct biologic system. The same monkey was used for all but two studies. Additional monkeys were used for injection of CHD-LDL from a normal subject and for the simultaneous injection of native and CHD-LDL from MPD-11. The animals were maintained on standard monkey chow during the 48 to 72 hour sampling period. For injections and blood withdrawal, the animals were sedated with ketamine, 10 mg/kg (Parke-Davis, Morris 'These subjects have previously been reported in reference 5.
Plains, New Jersey). Blood samples (2 to 3 ml) were obtained 30 to 60 minutes after injection and then 4 to 6 times over the following 48 to 72 hours. Plasma was isolated by centrifugation at 2000 rpm at 4°C and 125 I and 131 I radioactivity was determined. To block thyroidal uptake of radioactive iodide, the monkeys received 100 mg of potassium iodide before all studies.
In Vitro LDL Degradation Studies
Studies of the degradation of 125 I-LDL and 12S I CHD-LDL by cultured human peripheral monocytederived macrophages and human fibroblasts were carried out using LDL from normal volunteers. Monocytes were isolated by the method of Fogelman et al. 17 The cells were plated in 35 mm dishes at a concentration of 1 x 10 6 cells per dish. The cells were maintained in RPMI 1640 containing 100 U/ml penicillin, 100 ug/ml streptomycin, 15 mM Hepes, pH 7.4 (medium A) and 20% autologous serum. The medium was changed every 2 to 3 days. After 5 to 7 days, studies were carried out as follows: Medium A was removed and replaced with RPM11640 containing 0.2% BSA, 15 mM Hepes, pH 7.4 (medium B) and 25 /xg of 125 I native or 25 /*g of 125 I-CHD-LDL Unlabeled native LDL (500 ptg) was added to some dishes to distinguish between high affinity receptorand nonreceptor-mediated degradation. After a 4-hour incubation period, degradation of radiolabeled LDL to trichloroacetic acid soluble iodopeptides in the media was measured as described by Ho et al. 18 Normal human fibroblasts were obtained from Jerrold Perlish of the Department of Dermatology. The cells were plated at a density of 1 x 10 5 per dish and grown in 35 mm dishes in Ham's F-10 containing 100 U/ml penicillin, 100 pig/ml streptomycin and 10% fetal calf serum. After 6 days in culture, when the cells were nearly confluent, the medium was changed to Medium A with 20% human lipoprotein deficient serum. After an additional 24 hours, degradation studies were then carried out in the manner described for monocyte-derived macrophages using Medium B. Degradation was calculated as nanograms of 
Other Methods
Plasma triglyceride and cholesterol levels were quantitated by enzymatic methods using an ABA-100 automated spectrophotometer (Abbott Laboratories, Chicago, Illinois). Lipoprotein cholesterol levels were obtained using LJpid Research Clinic methodology. 19 LDL apo B concentration was determined by radioimmunoassay using a goat antiserum to human apo B. Radiolabeled and unlabeled LDL were used for the tracer and standards respectively. The interassay coefficient of variation for this assay was 9%. Agarose electrophoresis was performed according to the method of Noble. 20 Amino acid analysis (kindly performed by David Wang-lverson) was carried out on a D-500 Amino Acid Analyzer (Dionex, Sunnyvale, California) using mercaptoacetic acid to allow determination of the number of CHD-modified arginine residues as described by Mahley et a!.
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Analysis
The FCRs for native and CHD-LDL in the human studies were obtained from specific radioactivity data using a two-pool model that included intravascular and extravascular compartments as suggested by Langer et al. 14 The experimental data were fitted using a multicompartmental computer program developed at Columbia University College of Physicians and Surgeons by R. Ramakrishnan. The initial specific activity of each tracer was determined by extrapolation of the decay curves back to zero time based on five values obtained during the first 6 hours of each study. All subsequent data were then normalized using the initial specific radioactivity before kinetic analysis. The two-pool model of Langer et al.
14 was also used to calculate the FCR in studies carried out in the cynomolgus monkey. Statistical analysis was performed using Student's f-Test for unpaired data and the Wilcoxon Rank Sum Test. The latter was used when the distribution of one or both variables was not normal.
Results
The clinical characteristics of the study subjects are presented in Table 1 . The MPD subjects were significantly older than the control subjects (Table 1) .
However, their percentage ideal body weights were similar. Total and LDL cholesterol levels were reduced in the MPD compared to those of the controls. The two subjects with familial hypercholesterolemia had elevated plasma total and LDL cholesterol concentrations.
All LDL preparations used for in vivo and in vitro studies were characterized by agarose electrophoresis before the start of each study. An example of the relative electrophoretic mobilities of native and CHD-LDL is depicted in Figure 1 . All preparations of CHD-LDL moved as a single band exhibiting faster migration than the native lipoprotein. 10 Based on amino acid analysis, between 40% and 55% of the arginine residues in the LDL preparations used in the in vivo studies were modified by CHD. Table 2 presents the total FCR for LDL apo B degradation, which was experimentally determined from the apo B specific radioactivity data after injection of radiolabeled native LDL; and the FCR for CHD-LDL apo B degradation, which was experimentally determined from the apo B specific radioactivity data after injection of radiolabeled CHD-LDL. As reported previously in a smaller group of patients, 5 the mean FCR for native LDL in the MPD subjects was significantly higher than that of the control subjects (0.78 ± 0.32 vs 0.45 ± 0.11 day" 1 , p< 0.01). The MPD subjects had a wide range of total FCR values and there was an inverse relationship between the total FCR and LDL cholesterol concentration of the eleven subjects (r = -0.68; p < 0.05). The FCRs of 0.28 and 0.12 day 1 in the mother and daughter with heterozygous and homozygous FH are quite similar to those reported by other investigators for individuals with these disorders. 2021 In addition, studies of native LDL degradation by their monocyte-derived macrophages demonstrated 45% and 5% of normal high affinity degradation rates in the mother and daughter respectively (data not shown).
The FCR of CHD-LDL was also elevated in five of the six MPD subjects vs the controls and the difference between the mean values for each group (0.62 ± 0.53 vs 0.23 ± 0.04 day-1 ) was significant (p < 0.01). The mean FCR for CHD-LDL in the MPD group was 71% ± 18% of the total FCR for native LDL. The mean FCR for CHD-LDL in the control 'Total = the fractional catabolic rate derived from the specific radioactivity decay curve after injection of 125 I native LDL.
tCHD-LDL = the fractional catabolic rate derived from the specific radioactivity decay curve after injection of 125 I cyclohexanedione LDL. Statistical analysis of the variables was performed with the Wilcoxon Rank Sum Test.
+ These subjects have previously been reported in reference 5. No data related to CHD-LDL was presented in that report, however. subjects was 61% ± 6% of the total FCR. These data are compared graphically in Figure 2 . In contrast, in the FH patients, the FCR for both native and CHD-LDL were reduced. There was essentially no difference between the two FCRs in the homozygous subject.
To eliminate the possibility that a systematic difference in the degree of CHD modification of LDL preparations from patients and controls was the basis of our results, we injected several of the CHD-LDL preparations used in the human turnover studies into cynomolgus monkeys (Table 3 ). All CHD-modified LDL preparations were handled in a similar manner by the three monkeys used. Cynomolgus monkeys were also used to directly compare radiolabeled native LDL preparations. Native LDL preparations from MPD subjects were not removed more rapidly from plasma than native LDL from normal subjects. In addition, the FCR of each of the native LDL prepara- The absolute rates are presented in parentheses within each portion of the whole bar. The increased proportion of the total fractional catabolic rate that may be associated with nonreceptor pathways (using the FCR of CHD-LDL as a measure of catabolism via this pathway) is evident in the myeloproliferative subjects (MPD) vs controls. All studies were carried out with preparations that had been prepared for injection into the subjects themselves except the study of MPD-8 in which the radiolabeled native and CHD-LDL were reisolated from that subject 48 hours after injection. Radiolabeled native and CHD-LDL were also reisolated from MPD-11 and injected into the monkey 4 days after injection of the Initial preparations. The data for MPD-11 shown here is for the initial preparations. Figure 3 compares the removal of the "nonscreened" and reisolated preparations from that subject by the monkey. Three monkeys were used for these studies. One monkey received CHD-LDL from a normal subject; one monkey was used to study the native and CHD-LDL preparations from MPD-11; the third monkey was used in all of the other studies.
tions was significantly greater (two to four times) than the FCR of their CHD-modified counterparts in these monkeys. Finally, two experiments were performed to rule out in vivo reversal of the CHD modification in subjects with MPD. Native and CHD-LDL from MPD No. 8 and No. 11 were reisolated by ultracentrifugation of a sample of plasma obtained 48 hours after these subjects had received autologous radiolabeled lipoproteins by intravenous injection. The reisolated preparations in each case were simultaneously injected into a monkey. Thus, in this instance, the monkey received native and CHD-LDL that had been biologically screened in these MPD subjects. In the case of MPD No. 8, the calculated FCR of the reisolated CHD-LDL preparation was not different from those of its nonscreened counterparts from other normal and MPD subjects and was reduced by 50% as compared to the FCR of the reisolated native LDL. In the case of MPD No. 11, both nonscreened and screened (reisolated 48 hours after injection) native and CHD-LDL were compared in the same monkey in studies performed 4 days apart. Although low levels of radioactivity in the reisolated sample did not permit calculation of the FCR of the native and CHD-LDL preparations after injection into the monkey, it is clear (Figure 3) that the large differences observed in the early rates of clearance of the two forms of nonscreened LDL after injection into the monkey were still present after those lipoproteins had circulated for 48 hours in the patient.
Mahley and his coworkers 10 had described the effects of CHD modification of arginine residues in LDL upon binding and degradation of LDL by normal human fibroblasts. We have compared the degradation of native and CHD-LDL (from normal volunteers) by human fibroblasts and human monocyte-derived macrophages. The results of these studies (Table 4) demonstrated that CHD-LDL preparations with electrophoretic mobility and degree of substitution identical to those present in preparations used for in vivo studies showed 9% to 39% of the high affinity degradation that occurred when native LDL was presented to monocyte-macrophages. When LDL and CHD-LDL preparations from the same source were simultaneously studied in monocyte-derived macrophages and fibroblasts, the latter cells degraded CHD-LDL at a level equal to 18% of the rate at which they degraded native LDL, while in the former cells, CHD-LDL was degraded at 28% of the rate observed for native LDL.
Discussion
We have previously demonstrated that LDL cholesterol levels are significantly reduced in subjects with myeloid metaplasia and polycythemia vera 4 and that this state is associated with an increased catabolism of native LDL apo B in this group. 5 In the present study, we have further defined the abnormality in MPD subjects by demonstrating an increase in the catabolism of CHD-LDL. Shepherd and coworkers, using the method of Mahley et al. 10 to modify LDL with CHD, first attempted to quantitate in vivo, receptor-and nonreceptormediated LDL catabolism. From their data they concluded that approximately 60% of LDL catabolism occurred via nonreceptor routes in normal subjects and that this pathway accounted for 70% to 80% of LDL degradation in subjects with heterozygous FH in whom the total FCR of LDL apo B was reduced. 12 More recently, Thompson et al. 22 carried out similar tHigh affinity degradation is calculated as the difference between the TCA soluble iodopeptide formed from 25 fig  125 I native or CHD-LDL in the absence and in the presence of 500 ng unlabeled native LDL during the 4-hour incubation period (see Methods). studies in subjects with homozygous FH and concluded that there was essentially no receptor-mediated degradation of LDL in these individuals with markedly reduced catabolism of native LDL. 22 Our findings in five normal individuals and two FH subjects who received CHD-LDL are quite consistent with the data of Shepherd et al. 12 and Thompson et al. 22 In contrast, the increases in the absolute fractional rates of catabolism of both native and CHD-LDL from plasma in the MPD group was an unexpected finding. Increases in the catabolism of native LDL have been demonstrated in heterozygous FH patients after treatment with cholestyramine 22 -23 and in one hypothyroid subject treated with thyroid hormone. 22 In addition, Thompson et al. 22 reported increases in the degradation of CHD-LDL in a normal subject and a homozygous FH subject after plasma exchange and in a hypothyroid subject after therapy with thyroid hormone. In both patients, the FCR of CHD-LDL was still reduced in comparison to that observed in normal subjects. In contrast, in five of six untreated MPD subjects, the FCR for CHD-LDL was well above that seen in normal subjects (Table 2) . Based on the published works of Shepherd 1223 and Thompson et al. 22 one might conclude from the present results that individuals with MPD have increased nonreceptor-mediated catabolism of LDL.
This conclusion, however, is dependent on several assumptions concerning the use of CHD-LDL as a valid tracer of in vivo, nonreceptor-mediated degradation of LDL. First, although the study of Mahley et al. 10 indicated that increasing CHD modification of the arginine residues of LDL resulted in decreasing specific binding and receptor-mediated degradation of native LDL by fibroblasts, those investigators were not able to completely inhibit these activities. Thus, although Thompson et al. 22 and the present study demonstrated that native and CHD-LDL had identical rates of removal from plasma in homozygous FH subjects, the lack of specific LDL receptors in these patients does not permit one to conclude that there would be no interaction of CHD-LDL with the native LDL receptor in other subjects. Such interaction would explain the higher FCR seen for CHD-LDL in normal subjects 12 compared to that observed in homozygous FH individuals in the study by Thompson et al. 22 and in the present report. The discrepancy could result from insufficient modification of arginine residues by CHD. 10 ' 12 In both the study by Shepherd et al. 12 and in the present work, approximately 15% to 20% residual capacity to bind to specific LDL receptors was probably present in the CHD-LDL preparations used in vivo. Our results are presented with that caveat in mind. However, this degree of persistent receptor-mediated catabolism of all the CHD-LDL preparations in vivo would not alter the conclusion we have reached. Thus the magnitude of the difference in the FCR of CHD-LDL between subjects with MPD and control subjects is greater than that which could be accounted for by residual receptormediated degradation of the CHD-LDL.
Two further assumptions crucial to interpretation of the present data concern the degree of modification of the CHD-LDL in the control and MPD groups, and the stability of the modification. These assumptions were tested using the cynomolgus monkey as a biologic screen. The results in Table 3 clearly indicate that these animals removed CHD-LDL from plasma at a slower rate than that observed for native LDL and that they did not discriminate between CHD-LDL from normal, FH, or MPD donors. Studies where CHD-LDL was reisolated from MPD subjects 48 hours after they had received it and injected into monkeys indicated that the labeled CHD-LDL preparations were not altered during circulation in those subjects. Shepherd et al. 12 and Thompson et al. 22 have also presented data supporting the in vivo stability of CHD-LDL. Recently, Slater et al. 24 further demonstrated that although some reversal of the CHD modification could be demonstrated in an in vitro system after incubation of the CHD-LDL at 37°C, incubation of modified LDL at this temperature for 24 hours in vitro as well as "incubation" in vivo did not affect its rate of removal from plasma after injection into rabbits. Although not all our LDL preparations could be tested, these data support our conclusion that the increased FCR for autologous CHD-LDL in the MPD patients was a true biologic phenomenon unique to this group. The studies in monkeys also indicated that the more rapid FCR of native and CHD-LDL in MPD was not the result of abnormalities in their lipoproteins, but appeared to be a function of the removal system.
The most crucial assumption related to the use of CHD-LDL as an in vivo tracer in these studies was that nonreceptor-mediated degradation of both native and modified LDL was identical in the two study groups. This was particularly relevant in our subjects who have neoplastic cells as well as a significantly increased mass of activated monocyte-macrophages. 25 If either neoplastic cells or activated macrophages in the MPD subjects degraded CHD-LDL via the nonreceptor pathway at a faster rate than they degraded native LDL via that same pathway, then quantitation of nonreceptor-and receptor-mediated degradation of native LDL would be impossible. In an initial attempt to address this problem, we studied the in vitro degradation of native and CHD-LDL in cultured monocyte-derived macrophages obtained from normal volunteers. The data in Table 4 indicate that degradation of CHD-LDL (approximately 45% of the arginine residues modified) by these cells was significantly reduced compared to that of native LDL. We also observed that the degradation of the LDL preparations by normal fibroblasts was similar to that by monocytes. The CHD-LDL was degraded at rates expected for the degrees of substitution we demonstrated by amino acid analysis of several preparations. 10 Thus, although we feel that CHD-LDL is a valid tracer of nonreceptor-mediated catabolism of native LDL in subjects with MPD, direct in vitro studies of native and CHD-LDL degradation by circulat-ing monocyte macrophages from subjects with MPD will be necessary to clarify this issue.
As noted above, both neoplastic cells and activated monocyte-macrophages are candidates for the cell type responsible for increased catabolism of native and CHD-LDL. Cells that have undergone malignant transformation are known to have altered cholesterol metabolism, 26 " 28 and increased in vitro receptor-mediated degradation of LDL by mononuclear cells isolated from subjects with acute myelogenous leukemia has been demonstrated by Ho et al. 29 Acute myelogenous leukemia is characterized by large numbers of immature, rapidly proliferating cells. It is not surprising then, that in the latter disease, decreased intracellular cholesterol levels and increased rates of cholesterol synthesis by myeloblasts, have also been observed. 30 Although extrapolation of these in vitro data to the in vivo situation would lead one to expect an increase in receptor-mediated LDL catabolism, we have no data that would rule out increased nonreceptor degradation of LDL by neoplastic cells as the basis of our results. A combination of abnormalities in both pathways is also possible and was suggested by the data in MPD No. 8 and No. 11.
Monocyte macrophages are both increased in number and demonstrate signs of increased activity in MPD. Bases and Krakoff 25 noted increased removal from plasma of heat-aggregated albumin injected into subjects with MPD and concluded that this was evidence of increased activity of the "reticulo-endothelial system." Human monocyte-derived macrophages can bind and degrade native LDL via specific high affinity receptors. 30 In addition, these cells can internalize and degrade LDL that has been modified to increase its negative charge via a specific "scavenger receptor pathway." 3031 Finally, both native and modified LDL might be catabolized via nonspecific uptake of LDL as the result of fluid phase endocytosis or phagocytosis. Increased activity of the latter pathway would increase the FCR of both native and CHD-LDL in vivo and might be the basis for our findings. The recent report by Slater et al. 32 indicating an important role of the "reticuloendothelial system" in the catabolism of CHD-LDL supports our hypothesis.
The demonstration of increased LDL catabolism in these subjects is intriguing from two standpoints. First, if neoplastic cells can be a major site of LDL degradation, whether via receptor or nonreceptor mechanisms, LDL may be useful as a targeted vehicle for chemotherapy. This possibility has been raised by other investigators 3334 and is worthy of serious investigation. Second, if activated monocyte macrophages can account for a major proportion of LDL catabolism by nonreceptor pathways, possibly via increased nonspecific endocytosis, then studies of monocyte macrophages isolated from individuals with MPD might offer new insights into the development of the lipid-laden cells present in atherosclerotic lesions.
